Introduction: Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and
remain <10%. [2] [3] [4] Proceeding to a successful curative stem cell transplant (SCT) in the relapsed setting is possible for only a minor proportion of R/R patients. Encouragingly, targeted therapeutic options for AML patients harboring certain mutations (i.e., IDH2, FLT3) or surface markers (i.e., CD33) now exist, improving upon the standard of care and generating hope for effective small molecule and targeted strategies for additional AML subsets. [5] [6] [7] The antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL2) is overexpressed in hematologic malignancies, where it has been implicated in the maintenance and survival of AML cells, therapeutic resistance, and associates with poor overall survival in AML patients. 8, 9 In addition to AML, aberrant BCL2 overexpression is identified in patients with high-risk myelodysplastic syndromes (MDS), and in vitro sensitivity to BCL2 inhibition in primary samples from patients with high-risk MDS or secondary AML has been characterized. 10, 11 BCL2 overexpression has also been identified in a majority of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive myeloid malignancy of older adults with a median survival under 1 year. 12 Venetoclax (VEN) is an oral, potent, and selective BCL2 inhibitor, FDA approved in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL) and 17p deletion. 13 As a single agent for patients with R/R AML, VEN has demonstrated clinical activity, 14 although responses were relatively modest and short-lived.
Synergistic activity against myeloid malignancies is seen in vitro
and in vivo with VEN in combination with lower intensity antileukemia therapy, such as low-dose cytarabine (LDAC) or hypomethylating agents (HMA) (i.e., azacitidine or decitabine). 8, 9, 15, 16 Clinical data are now also available, demonstrating encouraging safety and efficacy in treatment-naive elderly and/or unfit AML patients, with VEN in combination with either LDAC (NCT02287233), or the HMAs azacitidine or decitabine (NCT02203773), leading to FDA breakthrough designations for these treatment combinations. 17, 18 VEN combination strategies for the treatment of patients with relapsed/refractory AML and/or related myeloid malignancies such as myelodysplastic syndromes (MDS) and BPDCN have not been previously reported. Herein we report our experience and results of VEN in combination approaches for patients with myeloid malignancies in the salvage setting.
| M E TH ODS
To determine the efficacy of VEN combinations in the salvage setting, we reviewed all adult patients treated at our institution with a relapsed and/or refractory myeloid malignancy (including AML, MDS, and had TP53 mutations, and 11 (26%) patients had IDH1 or IDH2 mutations. Additional mutations and frequencies are provided in Table 1 .
| Treatment characteristics
In combination with VEN, the majority of patients received either decitabine (n 5 23, 53%) or azacitidine (n 5 8, 19%); including 21 (68%) patients who had received HMA therapy as a prior salvage regimen. Additional details regarding VEN combination treatment strategies received are provided in Table 1 .
Thirty-seven (86%) patients received VEN dose reductions due to patient requirements for concurrent CYP3A4 and/or P-glycoprotein (PGP) inhibitors. 23, 24 VEN was administered at a median dose of 300 mg (100-400 mg) in combination with the moderate CYP3A4 inhibitors isavuconazonium or fluconazole (n 5 8, 19%), 200 mg (100-400 mg) in combination with the strong CYP3A4 inhibitor voriconazole (n 5 13, 30%), and 100 mg (100-400 mg) in combination with the strong CYP3A4 inhibitor posaconazole (n 5 16, 37%). In addition to azole antifungals, patients also received other known CYP3A4 and PGP inhibitors during treatment including ciprofloxacin (n 5 14, 33%), amiodarone (n 5 3, 7%), diltiazem (n 5 2, 5%), and carvedilol (n 5 1, 2%).
| Safety
Tumor lysis syndrome (TLS) prophylaxis with allopurinol was administered at least one day prior and during the initial venetoclax dose Table 2 . Three patients (7%) received growth factor support (i.e., GCSF) at any time during VEN combination treatment, and 6 (14%) patients were hospitalized throughout their entire treatment duration.
| Response
Overall, patients received a median of 2 cycles of treatment (range, 1-4), and seven patients (16%) received 3 or more cycles of therapy.
Objective response rate (ORR) by IWG criteria was achieved in 9 (21%) patients, including 2 (5%) complete response (CR), 3 (7%) complete response with incomplete blood count recovery of either ANC or platelets (CRi), and 4 (9%) achieving morphologic leukemia-free state (MLFS) ( Table 3 ). The 9 patients with ORR had received a median of 2 (range, At the time of data cutoff, the median overall survival was 3.0 months (range, 0.5-8.0) and estimated 6-month survival was 24%.
Median overall survival in the 9 responding patients was 4.8 months Patients treated with VEN combinations for R/R disease at our institution represented a heavily pretreated, older, and high-risk population, with the majority of patients (58%) over age 65 and treated in the salvage-3 setting or beyond. Nearly one-third (31%) of patients received prior treatment for AHD, 12% of patients had previously Hospitalized for entire duration of therapy-no. (%) 6 (14) Abbreviations: WBC, white blood cell count; ANC, absolute neutrophil count. a May be counted more than once. b Urinary tract infection (n 5 2), perirectal abscess (n 5 2), and n 5 1 of colitis, fungal pneumonia, HSV cellulitis. c Sinusitis (n 5 2), HSV cellulitis (n 5 2), colitis (n 5 2), and n 5 1 of perirectal abscess, Clostridium difficile colitis, appendicitis, Clostridium bacteremia, septic joint, BK virus cystitis, and diverticulitis. As has been previously described, 25 27 In addition, future evaluation of BCL2 family sensitivity index and BH3 profiling to evaluate for the presence or absence of BCL-XL and MCL-1 resistance mechanisms will be important to clarify whether this can predict patients most likely to benefit from VEN treatment. 15, 28 Current evidence recommends a VEN treatment dose of 400 mg in combination with HMA therapy, and 600 mg of VEN in combination with LDAC. In the setting of concomitant CYP3A4 inhibitors such as the frequently utilized oral azole antifungals, VEN doses are recommended to be reduced by 50% for moderate CYP3A4 inhibitors such as fluconazole or isavuconazole, and by at least 75% for strong CYP3A4 inhibitors such as posaconazole or voriconazole, to achieve equivalent dosages. 23 In this cohort of 43 patients with multiply relapsed/refractory disease, 37 (86%) patients required concomitant azole antifungal therapy. Eighteen (50%) patients received the 
